Benzinga | Aug 12, 2021 05:09PM EDT

Trevi Therapeutics Q2 EPS $(0.49) Misses $(0.48) Estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 19.51 percent decrease over losses of $(0.41) per share from the same period last year.